A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)

Trial Profile

A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Sep 2017

At a glance

  • Drugs Esaxerenone (Primary) ; Eplerenone
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms ESAX-HTN
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 24 Sep 2017 According to an Exelixis media release, Daiichi Sankyo will submit a Japanese regulatory application for esaxerenone for an essential hypertension indication in the first quarter of 2018.
    • 24 Sep 2017 According to an Exelixis media release, Daiichi Sankyo plans to disclose the detailed study results at future scientific meetings.
    • 24 Sep 2017 Primary endpoint Change from baseline in sitting systolic and diastolic blood pressure has been met according to an Exelixis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top